On March 18, 2010
Don’t Bet Against Avastin: Roche’s $55,000 Cancer Drug Thrives on Bad News
Usually, when drugs fail in multiple tests, their sales decline. Not Roche (RHHBY)’s cancer treatment Avastin. Its sales go up. And they’ll probably continue going up, despite negative headlines.
No tags for this post.
0 Comments